Home → Bipolar Disorder Treatment

Bipolar Disorder: Expert Psychiatrist Guide to Diagnosis and Treatment

By Ryan S. Sultan, MD
Assistant Professor of Clinical Psychiatry, Columbia University Irving Medical Center
Board-Certified in Adult Psychiatry and Child & Adolescent Psychiatry
March 29, 2026

Understanding Bipolar Disorder: Types and Diagnosis

Bipolar I Disorder

Bipolar I is defined by the occurrence of at least one manic episode. Manic episodes involve a distinct period of abnormally elevated, expansive, or irritable mood AND persistently increased goal-directed activity or energy, lasting at least 7 days (or any duration if hospitalization is required).

During a manic episode, three or more of the following are present (four if mood is only irritable):

• Inflated self-esteem or grandiosity
• Decreased need for sleep (e.g., feels rested after 3 hours)
• More talkative than usual or pressure to keep talking
• Flight of ideas or subjective experience of racing thoughts
• Distractibility
• Increased goal-directed activity or psychomotor agitation
• Excessive involvement in risky activities (spending sprees, sexual indiscretions, foolish business investments)

Mania causes marked impairment in social or occupational functioning and may include psychotic features (delusions, hallucinations). The impairment is the key: mania is not just "feeling good" -- it involves judgment so impaired that patients may destroy relationships, deplete savings, get arrested, or require hospitalization. Most patients with bipolar I also experience major depressive episodes, though this is not required for diagnosis.

Bipolar II Disorder

Bipolar II involves at least one hypomanic episode and at least one major depressive episode, with no history of full mania. Hypomania involves the same symptoms as mania but is less severe (lasting at least 4 days), does not cause marked functional impairment, does not include psychotic features, and does not require hospitalization.

Bipolar II is commonly misunderstood as "milder bipolar." This is incorrect. While the highs are less extreme, patients with bipolar II often spend significantly more time in depressive episodes than those with bipolar I, and their overall functional impairment from depression can be equal or greater. The depressive burden of bipolar II is substantial, and these patients are at high suicide risk.

Cyclothymic Disorder

Cyclothymia involves chronic (2+ years) fluctuating mood disturbance with numerous periods of hypomanic symptoms and depressive symptoms that do not meet criteria for a hypomanic or major depressive episode. It can be thought of as a milder but chronic form of bipolar spectrum illness, and approximately 15-50% of individuals with cyclothymia eventually develop bipolar I or II.

The Challenge of Diagnosis: Why Bipolar Disorder Is Missed

Research consistently shows that bipolar disorder is one of the most commonly misdiagnosed psychiatric conditions. Studies suggest an average delay of 5-10 years between symptom onset and correct diagnosis, with patients seeing an average of 3-4 clinicians before receiving the correct diagnosis.

Why does this happen?

• Depression comes first: Most patients present for treatment during depressive episodes. If the clinician does not specifically ask about past manic or hypomanic episodes, the bipolar diagnosis is missed.
• Hypomania feels good: Patients with bipolar II may not report hypomania because it feels productive and enjoyable. They do not see increased energy, decreased need for sleep, and heightened creativity as problems -- they see them as their "best self."
• Overlap with other conditions: Bipolar disorder symptoms can mimic ADHD (impulsivity, distractibility, restlessness), borderline personality disorder (mood instability, impulsivity), unipolar depression, anxiety disorders, and substance use disorders.
• Inadequate assessment: Many clinicians use brief symptom checklists rather than comprehensive longitudinal assessments. A 15-minute medication check is insufficient to detect bipolar disorder.

Why misdiagnosis matters: Treating bipolar depression with antidepressants alone (without a mood stabilizer) can trigger manic or hypomanic episodes, induce rapid cycling (frequent mood switches), cause mixed episodes (simultaneous manic and depressive symptoms, which carry the highest suicide risk), and create a more treatment-resistant illness over time.

Neurobiology of Bipolar Disorder

Bipolar disorder has strong genetic underpinnings -- heritability is estimated at 60-85%, among the highest of any psychiatric condition. First-degree relatives of individuals with bipolar disorder have a 5-10 fold increased risk compared to the general population.

At the neural circuit level, bipolar disorder involves dysregulation of prefrontal-limbic circuits that govern emotional regulation. During mania, there is reduced prefrontal cortical activity (diminished "braking" on emotions and impulses) with increased limbic and striatal activity (heightened reward sensitivity and emotional reactivity). During depression, both prefrontal and limbic activity patterns shift, with excessive default mode network engagement driving rumination.

Neurotransmitter systems implicated include dopamine (elevated during mania, reduced during depression), serotonin (disrupted in both phases), glutamate (excitatory imbalance), and GABA (inhibitory deficits). Circadian rhythm disruption is increasingly recognized as a core feature of bipolar disorder, with disrupted sleep-wake cycles both triggering and being caused by mood episodes.

Mood Stabilizers: The Foundation of Bipolar Treatment

Lithium

Lithium has been the cornerstone of bipolar treatment since the 1960s and remains one of the most effective options. It is the only psychiatric medication conclusively shown to reduce suicide risk -- a critically important property given that bipolar disorder carries a lifetime suicide risk of 15-20%.

Strengths: Highly effective for preventing manic episodes, reduces suicide risk by 60-80%, effective for long-term maintenance, neuroprotective (may increase gray matter volume), and well-studied with over 60 years of clinical data.

Monitoring requirements: Blood lithium levels (target 0.6-1.2 mEq/L), kidney function (creatinine, BUN) every 6-12 months, thyroid function (TSH) every 6-12 months, and calcium levels. Lithium has a narrow therapeutic index, meaning the difference between a therapeutic dose and a toxic dose is relatively small. Dehydration, NSAIDs, ACE inhibitors, and other factors can raise lithium levels dangerously.

Side effects: Thirst and increased urination (polyuria/polydipsia), tremor, weight gain, thyroid suppression (hypothyroidism in 5-35% of long-term users), kidney effects (reduced concentrating ability, rare nephrogenic diabetes insipidus), acne, and cognitive dulling. Many side effects are dose-dependent and manageable.

Valproate (Depakote)

Valproic acid/divalproex sodium is effective for acute mania and maintenance treatment. It may be particularly useful for mixed episodes and rapid-cycling bipolar disorder. Monitoring requirements include blood valproate levels (target 50-125 mcg/mL), liver function tests, CBC, and for women of childbearing age, pregnancy testing -- valproate is a known teratogen (causes neural tube defects) and is generally avoided in women who may become pregnant.

Lamotrigine (Lamictal)

Lamotrigine is primarily effective for preventing bipolar depressive episodes and is a first-line option for bipolar II disorder, where depression is the predominant burden. It has a favorable side effect profile (minimal weight gain, no metabolic effects, no blood level monitoring required for efficacy) but requires very slow titration due to the risk of Stevens-Johnson syndrome (SJS), a potentially life-threatening skin reaction. The standard titration starts at 25 mg daily and increases every 2 weeks, reaching therapeutic doses (200-400 mg) over approximately 6-8 weeks.

Carbamazepine (Tegretol)

Carbamazepine is effective for acute mania and maintenance treatment. It is used less commonly than lithium and valproate due to its drug interaction profile (it is a potent CYP450 inducer, reducing levels of many medications including oral contraceptives) and its side effect profile (sedation, ataxia, hyponatremia, rare aplastic anemia and agranulocytosis requiring CBC monitoring).

Atypical Antipsychotics in Bipolar Disorder

Atypical antipsychotics have become a major component of bipolar treatment, with several FDA-approved for acute mania, bipolar depression, or maintenance treatment.

For acute mania: Aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, asenapine, and cariprazine all have FDA approval.

For bipolar depression: Quetiapine (Seroquel), lurasidone (Latuda), cariprazine (Vraylar), and the olanzapine-fluoxetine combination (Symbyax) are FDA-approved. These are generally preferred over antidepressants for treating bipolar depression because they do not carry the risk of triggering mania.

Metabolic monitoring: Atypical antipsychotics carry risks of weight gain, dyslipidemia, hyperglycemia, and metabolic syndrome. Olanzapine and quetiapine are the highest-risk for metabolic effects, while aripiprazole, ziprasidone, and lurasidone are lower-risk. Regular monitoring of weight, fasting glucose, lipids, and waist circumference is essential -- this is something my JAMA research on antipsychotic prescribing patterns highlighted as often inadequate in clinical practice.

ADHD and Bipolar Disorder: A Challenging Overlap

The overlap between ADHD and bipolar disorder is one of the most challenging diagnostic and treatment dilemmas in psychiatry. Both conditions involve impulsivity, distractibility, hyperactivity/restlessness, difficulty with sustained attention, and emotional dysregulation. The key differentiating factor is episodicity.

Treating both conditions: When ADHD and bipolar disorder co-occur, the standard approach is to stabilize the mood first with a mood stabilizer or atypical antipsychotic before introducing a stimulant. Stimulants can potentially destabilize mood in bipolar patients, though the risk appears lower when mood is adequately stabilized. Non-stimulant options (atomoxetine, guanfacine) may be considered as lower-risk alternatives. Close monitoring is essential regardless of approach.

Substance Use and Bipolar Disorder

Substance use disorders co-occur in 40-60% of individuals with bipolar disorder, one of the highest comorbidity rates of any psychiatric condition. This is an area where my research expertise in substance use and psychiatric comorbidity directly informs my clinical approach.

Common substances used by bipolar patients:

• Alcohol: The most common, used during both manic and depressive episodes. Alcohol worsens mood instability, impairs medication adherence, increases impulsivity, and potentiates medication side effects.
• Cannabis: Often used to self-medicate anxiety or insomnia. My research shows that cannabis can trigger manic episodes, worsen psychotic symptoms during mania, and impair the effectiveness of mood stabilizers.
• Cocaine and stimulants: Can trigger or prolong manic episodes and increase psychosis risk.
• Opioids: Comorbid opioid use disorder requires integrated treatment with medication-assisted therapy (buprenorphine or methadone) alongside mood stabilizers.

Effective treatment requires integrated dual-diagnosis care -- addressing both the bipolar disorder and the substance use simultaneously rather than telling the patient to "get sober first" and then treating the mood disorder, which is an outdated and ineffective approach.

Sleep and Circadian Rhythm in Bipolar Disorder

Circadian rhythm disruption is increasingly recognized as not just a symptom but a potential mechanism driving bipolar episodes. Sleep deprivation is one of the most potent triggers for mania -- a single night of lost sleep can precipitate a manic episode in a vulnerable individual.

Clinical implications: I counsel all my bipolar patients to maintain strict sleep hygiene, prioritize consistent sleep-wake times (even on weekends), avoid shift work if possible, be cautious with travel across time zones, and report any changes in sleep patterns immediately. Social rhythm therapy (SRT), which focuses on maintaining regular daily routines and sleep patterns, has evidence for reducing mood episode recurrence when combined with medication.

Pregnancy and Bipolar Disorder

Managing bipolar disorder during pregnancy requires careful risk-benefit analysis because most mood stabilizers carry some teratogenic risk.

• Valproate: Contraindicated in pregnancy (high risk of neural tube defects, cognitive effects in offspring). Should not be used in women of childbearing age without reliable contraception and informed discussion.
• Lithium: Small increased risk of Ebstein's anomaly (cardiac malformation), but the absolute risk is lower than previously estimated (approximately 1 in 1,000 vs. baseline of 1 in 20,000). May be used when benefits clearly outweigh risks, with fetal echocardiography at 16-20 weeks.
• Lamotrigine: Appears to have the most favorable safety profile in pregnancy among mood stabilizers. Levels decrease during pregnancy and need monitoring/dose adjustment.
• Atypical antipsychotics: Growing data suggest relative safety, though long-term data on offspring development are limited.

Untreated bipolar disorder during pregnancy also carries significant risks -- increased substance use, poor prenatal care, impulsive behavior during mania, and severe depression with suicide risk. The decision to continue, modify, or discontinue medication during pregnancy should be made collaboratively between the patient, psychiatrist, and obstetrician.

My Approach to Bipolar Disorder

At Integrative Psych in Chelsea, Manhattan, I approach bipolar disorder with the comprehensive, research-informed perspective that comes from my position at Columbia University.

Key elements of my approach:

• Thorough diagnostic assessment: I conduct a comprehensive longitudinal evaluation -- not a 15-minute symptom checklist. I gather collateral history from family members (who often observe manic/hypomanic symptoms the patient does not recognize), review prior treatment records, and carefully assess for ADHD, anxiety, substance use, and other comorbidities.
• Evidence-based medication selection: I choose medications based on the specific bipolar subtype, predominant polarity (mania vs. depression-predominant), co-occurring conditions, metabolic risk factors, reproductive considerations, and patient preferences.
• Regular monitoring: Blood levels, metabolic parameters, thyroid function, kidney function (for lithium), and systematic assessment of mood symptoms at every visit.
• Psychoeducation: Helping patients and families understand the illness, recognize early warning signs of episodes, and develop action plans for intervention.
• Coordination with therapy: CBT for bipolar disorder, interpersonal and social rhythm therapy (IPSRT), and family-focused therapy all have evidence for reducing mood episode recurrence when combined with medication.

Further Reading

• Depression Treatment with Dr. Sultan
• Psychiatric Medication Management
• Ketamine Therapy for Depression
• Complete ADHD Guide